Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function

NCT01631097 is registered in ClinicalTrials.gov with AVEO Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01631097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01631097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function
Lead sponsor
AVEO Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2012
Completion date
January 31, 2014
Enrollment
44 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic impairment